Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
/ 5 items
#DFTX↓
Breakthrough LSD-Derived Drug DT120 Shows Dramatic Antidepressant Effect in Phase 3 Trial
Definium’s DT120 pill showed strong fast and lasting depression relief in Phase 3, with good safety and big symptom cuts.
Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
Jefferies Starts Coverage on Definium Therapeutics with Buy Rating and $30 Target
Jefferies initiated coverage on Definium Therapeutics with a Buy rating, citing strong Phase IIb results for its anxiety drug DT120 and high confidence ahead of Phase III trials.